Pegunigalsidase alfa (Protalix Biotherapeutics)

N/A

Report date: 2025/01/15 11:09:29

Base Information

Drug NamePegunigalsidase alfa (Protalix Biotherapeutics)
Drug Alias NameRecombinant human alpha galactosidase-AAlpha-galactosidaseModified recombinant human alpha-GAL-A proteinPegunigalsidase alfa-iwxjPegunigalsidase-alfa +[9] 
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of Actionα-Galactosidase replacements
Targetsα-Galactosidase
Therapy Area/IndicationsFabry Disease
Global Approved IndicationsFabry Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2023/05/04
Country/TerritoryCzechiaBelgiumCanada +[21] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesProtalix Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesProtalixChiesi Farmaceutici SPA
Inactive CompaniesProtalix Biotherapeutics Inc
Active IndicationsFabry Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A